Search
Close this search box.
Search
Subscriber Log In

In Case You Missed It: Three Things We Learned in Our 2024 Preview Webinar

evaluate-featured-image

Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our team talked through some of the highlights and discussed some of the stories behind the data, with a view to what it means for pharma […]

Sneak Peek at Our 2024 Preview Webinar

evaluate-featured-image

Fortunately, the annual Preview report that we publish at Evaluate is based on our consensus forecasting data. While that doesn’t guarantee accuracy – in the current market, guarantees are hard to come by – it does mean that the insight we share is based on some pretty solid data. The 2024 Preview report was published […]

2024 Preview: Are We There Yet?

are-we-there-yet-sign-featured-image

After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is […]

Themes from BIO Europe

Team-Photo

There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […]

In Case You Missed It: Three Things We Learned In Our World Preview Webinar

Case-You-Missed-Three-Things-We-Learned-Our-World-Preview-Webinar-featured-image

You may have read the report, you may have pondered the infographic, but the best way to really get under the skin of the Evaluate World Preview report is to join the webinar. As well as sharing the highlights of the data from the report, the webinar gave our presenters a chance to really discuss […]

Five Top Takeaways from BIO International 2023

Five-Top-Takeaways-BIO-International-2023-featured-image

A couple of weeks ago, we saw the return of BIO International to Boston for the first time since 2018. Since Boston is Evaluate’s home turf in the US, we headed to the gigantic Boston Convention Center to join 19,000 pharma, biotech and investment experts for four days of meetings, presentations, networking shindigs and sore […]

In Case You Missed It: Three Things We Learned In Our Gene Editing Webinar

Case-You-Missed-Three-Things-We-Learned-Our-Gene-Editing-Webinar-featured-image

Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as our home-grown specialists. And if that’s not enough, the webinar is available on demand. Gene editing is a hot topic right now. With the first Pdufa […]

Five Questions About the Future of Gene Editing

Five-Questions-About-Future-Gene-Editing-featured-image

Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a potential menace. Is it just going through the same growing pains as any new technology in the pharma industry? Or is it fundamentally […]

More in Hope than Expectation: Biopharma in 2023

More-Hope-than-Expectation-Biopharma-2023-featured-image

Few people are expecting biopharma to stage a spectacular comeback in 2023 but what can we reasonably hope for – and when? I joined the world of biopharma in 2022 and it seems I didn’t pick a vintage year. M&A activity was weak, share prices plummeted and IPOs were all but non-existent. However, I have […]